Volume | 0 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
XOMA Corporation | XOMA | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
25.36 |
Trades | Volume | Avg Volume | 52 Week Range |
---|---|---|---|
0 | 0 | - | 13.48 - 27.00 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
- | 0 | $ 25.36 | USD |
XOMA Corporation Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
294.83M | 11.63M | - | 4.76M | -40.83M | -3.51 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
XOMA News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical XOMA Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 24.46 | 26.79 | 24.46 | 25.68 | 10,265 | 0.90 | 3.68% |
1 Month | 24.05 | 27.00 | 23.4401 | 25.51 | 13,473 | 1.31 | 5.45% |
3 Months | 20.20 | 27.00 | 19.50 | 24.29 | 18,546 | 5.16 | 25.54% |
6 Months | 17.53 | 27.00 | 14.27 | 20.22 | 24,479 | 7.83 | 44.67% |
1 Year | 18.38 | 27.00 | 13.48 | 18.54 | 30,075 | 6.98 | 37.98% |
3 Years | 37.49 | 39.49 | 13.48 | 21.52 | 30,240 | -12.13 | -32.36% |
5 Years | 12.11 | 46.32 | 11.58 | 23.20 | 39,400 | 13.25 | 109.41% |
XOMA Description
XOMA Corp is a biotechnology royalty aggregator playing a unique role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. |